Omeran

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omeran

Omeran: Classification and Chemical Identity

The essential facts regarding this medicine can be summarized as follows: its active ingredient is Omeprazole, its primary form is the delayed-release capsule, its pharmacological class is the Proton Pump Inhibitor (PPI), its general therapeutic function is acid suppression, and its origin is a synthetic compound.

Omeran is a medicinal preparation whose active ingredient is Omeprazole, classified as a gastric antisecretory agent and a Proton Pump Inhibitor (PPI). This synthetic compound belongs to the chemical family of substituted benzimidazole derivatives, engineered for controlling acid levels. Omeprazole is a cornerstone in the treatment approach to acid-related disorders due to its strong, sustained action. This widely clinically recognized position indicates that the medication offers reliable and continuous control over gastric acidity.

What is the Purpose of a Proton Pump Inhibitor?

The primary general purpose of a Proton Pump Inhibitor like Omeran is to achieve a profound and sustained reduction of gastric acid output over time. The compound is designed to specifically target the H^+K^+-ATPase enzyme system, the Proton Pump, which performs the final step of acid secretion. This profound antisecretory action serves the general benefit of alleviating discomfort and supporting the natural healing of tissues exposed to acid, allowing for effective, long-term acid control.

Available Forms and Core Composition

The Omeprazole in Omeran is primarily available for oral administration in specialized delayed-release capsule or tablet formulations, as well as a sterile powder for injection for intravenous use. For the oral route, the active substance is formulated into specialized enteric-coated pellets. The need for this specialized coating is fundamental to the drug's identity, as it protects the acid-sensitive Omeprazole from being destroyed by the stomach's own acid before it can be absorbed.

Regulatory References

  1. Omeprazole Drug Information - MedlinePlus

What side effects are possible with Omeran?

Possible Side Effects and Safety Information

The safety profile of Omeran, which contains the active ingredient Omeprazole, is defined by officially documented adverse reactions and safety characteristics derived from government regulatory sources.

Adverse Reactions by Frequency and System-Organ Class

The following are officially classified side effects:

  • Common Reactions: These include gastrointestinal issues such as headache, abdominal pain, constipation, diarrhoea, flatulence, and nausea/vomiting. Benign fundic gland polyps are also listed as a common finding, particularly with long-term use.
  • Uncommon Reactions: Effects such as insomnia, dizziness, somnolence, rash, pruritus (itching), urticaria (hives), increased liver enzymes, and peripheral oedema are documented as uncommon.
  • Rare/Very Rare Reactions: The label also lists rare effects across various systems, including hypersensitivity reactions (e.g., angioedema, anaphylactic shock), changes in blood cell counts (e.g., leukopenia, agranulocytosis), and severe dermatological reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Serious Adverse Reactions and Duration-Related Safety

Official documents highlight certain clinically significant safety considerations:

  • Long-Term Exposure: Use for one year or more is associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine. Additionally, hypomagnesaemia (low magnesium levels) and Vitamin B-12 deficiency may occur with prolonged use.
  • Organ Systems: Rare, serious effects include acute tubulointerstitial nephritis (kidney inflammation) and hepatic failure; patients with pre-existing liver disease face a risk of encephalopathy.

Safety Restrictions and Notes

The official labeling includes safety limitations and specific notes:

  • Contraindications: Use is strictly prohibited for individuals with known hypersensitivity to any component of the formulation or to substituted benzimidazoles.
  • Diagnostic Interference: Due to the medicine's action, it may alleviate symptoms of an underlying gastric malignancy, potentially delaying diagnosis. The label also notes that increased Chromogranin A (CgA) levels may interfere with certain diagnostic tests for neuroendocrine tumors.
  • Infection Risk: PPI therapy may be associated with an increased risk of Clostridium difficile-Associated Diarrhea.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile for Omeran (Omeprazole) based on reported clinical manifestations and required emergency actions. Overdosage cases, including those involving doses up to 900 mg of the single substance, have been associated with a defined set of transient symptoms.

Documented Overdose Manifestations

Manifestations may include central nervous system effects such as confusion, drowsiness, and headache. Other documented signs involve the cardiovascular system, such as tachycardia, and autonomic effects like flushing, dry mouth, and diaphoresis (increased sweating). Nausea and blurred vision are also reported. Regulatory data indicates that reported overdose symptoms have typically been transient, and no serious clinical outcome has been documented following single-substance overdosage.

Required Emergency Actions

In the event of a suspected overdosage, the prescribing information explicitly mandates that individuals seek immediate medical attention. Contacting Poison Help or emergency medical services is the required first action. The regulatory strategy for management is to provide symptomatic and supportive treatment, as no specific antidote is known for omeprazole. The substance is also noted as being not readily dialyzable.

Therapeutic Uses of Omeran

What Omeran treats: main uses and benefits

Omeran, which contains the active ingredient omeprazole, is commonly used across conditions presenting with acute episodes where symptoms are linked to organ-specific functional stress in the upper gastrointestinal tract. It is applied in addressing symptoms related to systemic imbalance caused by excessive acid and is relevant for easing discomfort associated with systemic imbalance.

Omeran may be part of symptomatic management for conditions characterized by periods of heightened symptoms. It is applied in addressing symptomatic burden often associated with conditions like Gastroesophageal Reflux Disease (GERD), certain peptic ulcers (gastric and duodenal), and pathological hypersecretory conditions such as Zollinger-Ellison syndrome.

The medication is relevant for easing symptoms related to heightened physiological activity, such as heartburn and acid regurgitation, and is commonly used to help with symptoms related to inflammatory or irritative states. It supports patients during difficult episodes by easing distress and assists with maintaining functional stability when symptoms are more noticeable.

“This supportive relief contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.”

Quick Fact: Relief for Symptoms related to physical discomfort (e.g., heartburn)

Eligibility and Restrictions for Use

Omeran's official eligibility status is defined by regulatory bodies based on age, co-medication, and specific physical conditions.

Contraindicated Populations

Use is absolutely prohibited for patients who have known hypersensitivity to omeprazole, the substituted benzimidazole class, or any component of the formulation. The medicine is also contraindicated for patients concurrently receiving the antiretroviral drugs Nelfinavir or Rilpivirine.

Age-Related Eligibility

Age Group Official Regulatory Status
Adults (17+ years) Established for all approved uses.
Children (1–16 years) Established for GERD and Erosive Esophagitis.
Infants (< 1 month) Safety and efficacy have not been established.
Geriatric Patients May be more sensitive to effects, but no specific dose adjustment is mandated.

Conditional Use and Restrictions

Official labeling advises special caution for certain populations:

  • Hepatic Impairment: Patients with liver function issues (hepatic impairment) require monitoring, and dose reduction should be considered due to increased drug exposure.
  • Renal Impairment: No specific dose adjustment is officially necessary.
  • Reproductive Status: Use during pregnancy or lactation is generally reserved for situations where the potential benefit is assessed to outweigh any risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Omeran, containing omeprazole, defines interaction risks based on its effect on both gastric pH and the body's metabolic pathways.

Interaction Scope

Classification Affected Medicine or Product
Formally Contraindicated Rilpivirine-containing products (risk of reduced plasma levels)
Avoid Concomitant Use Clopidogrel (diminished antiplatelet activity)
Avoid Concomitant Use St. John's Wort, Rifampin (potential reduction in omeprazole concentration)
Not Recommended Atazanavir, Nelfinavir (reduced plasma levels via pH change)

Exposure Modification and Monitoring

Omeran can cause increased exposure of several co-administered drugs due to its inhibition of the CYP2C19 enzyme. This affects the elimination of substances such as Warfarin, Phenytoin, Diazepam, Cilostazol, and the immunosuppressant Tacrolimus; the regulatory label mandates monitoring for changes in the plasma levels of these drugs.

Conversely, the drug's acid-reducing effect reduces the absorption and decreases the plasma levels of medicines that require an acidic stomach environment for bioavailability, including Ketoconazole, Iron salts, and Ampicillin esters.

Interaction-Related Constraints

  • The anti-clotting effect of Clopidogrel is officially stated to be diminished by Omeran, and co-administration must be avoided.
  • For diagnostic investigations of neuroendocrine tumors, Omeran must be temporarily stopped for at least 14 days before assessing Chromogranin A ( CgA) levels due to potential test interference.
  • Patients taking Warfarin must be monitored for increases in INR and prothrombin time due to altered drug elimination.

Mechanism of Action

Omeran's Primary Target and Interaction

Omeran is a small molecule inhibitor of the XZ-1 kinase. It achieves its effect by selectively binding to the adenosine triphosphate (ATP) site on the enzyme's active domain. This non-covalent interaction demonstrates a high affinity and specificity for XZ-1 kinase over other closely related signaling molecules.

Intracellular Pathway Modulation

The binding of Omeran inhibits the enzymatic function of XZ-1 kinase. This interruption blocks the transfer of phosphate groups to target proteins, thereby affecting the phosphorylation of key downstream substrates, including p38 Mitogen-Activated Protein Kinase (MAPK). This action governs the inactivation of specific cellular transcription factors regulated by the XZ-1/p38 pathway.

System-Level Consequence

The resulting molecular cascade alters cellular responses, primarily within inflammatory signaling pathways. The inhibition leads to a reduced rate of synthesis and release of specific pro-inflammatory cytokines by the affected cell populations. This systemic consequence is the modulation of inflammatory marker levels in the physiological system.

Dosage and Administration Information

Omeran (Omeprazole) is administered via the oral route as delayed-release capsules, tablets, or granules for suspension, and also via the intravenous (IV) route for specific clinical scenarios when oral intake is not feasible. The oral forms are available in strengths such as 10 mg, 20 mg, and 40 mg. Standard adult oral dosing regimens typically follow a once daily frequency, but this is tailored based on the specific condition being addressed. For example, the treatment of erosive esophagitis requires 20 mg once daily for a typical course of four to eight weeks, while treatment of a gastric ulcer is typically 40 mg once daily. A twice-daily frequency is required when Omeran is used in combination regimens for H. pylori eradication.

Oral formulations must be taken before eating, preferably in the morning. To maintain the effectiveness of the protective gastro-resistant coating, the delayed-release capsule or tablet must be swallowed whole and must not be crushed or chewed. For patients unable to swallow an intact capsule, the contents (pellets) may be mixed with a small amount of soft food like applesauce and swallowed immediately without further manipulation. Dosages exceeding 80 mg per day, such as those used for pathological hypersecretory conditions, are generally administered in divided daily doses.

Administration rules are also specific to certain patient populations. Pediatric use is determined based on body weight for specific treatment courses. Additionally, patients with severe hepatic impairment may require a maximum daily dose not to exceed 20 mg. If a dose is missed, it should be taken as soon as possible, unless the next scheduled dose is due within 12 hours, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research evidence / Overview of studies for Omeran

Evidence for Symptom Management and Status in Esophageal Reflux (GERD)

Studies conducted during periods of increased symptom activity have used various Randomized Controlled Trials (RCTs) to explore the use of Omeprazole in populations experiencing Gastroesophageal Reflux Disease (GERD) symptoms. The trials typically monitored patient-reported outcomes describing perceived discomfort over defined time intervals. For individuals with the more severe Erosive Esophagitis (EE), research describes that studies monitored the patterns of endoscopic change of the inner lining. Studies describe patterns related to the change in symptom reporting and the measured patterns of endoscopic change within the short-term study periods. Long-term outcomes for patients managing GERD and EE over many years are not well characterized by the initial controlled studies.


Evidence for Ulcer Closure and Status in the Stomach and Duodenum

Omeprazole was evaluated in studies concerning ulcer closure and status in the stomach (benign gastric ulcers) and the upper part of the small intestine (duodenal ulcers). These trials were primarily conducted in adults and monitored status through endoscopic examination. In research contexts involving ulcers caused by the Helicobacter pylori bacteria, Omeprazole was used as part of a combination regimen with specific antibiotics. Findings related to ulcer status describe changes measured during the study period. The evidence for preventing future ulcer recurrence over a period exceeding one year is more limited.


Evidence in Specific or Vulnerable Populations and Research Gaps

Specific trials were conducted in defined pediatric populations, including both infants and older children, to examine symptoms related to reflux and the mucosal status in erosive esophagitis. Research also explored the role of Omeprazole in special hospital settings for critically ill patients. Data for certain subgroups—such as very young infants for long-term maintenance, or individuals with a complex range of comorbidities—remain insufficient, and subgroup findings are uncertain. One key limitation is that follow-up durations were limited in many initial controlled studies, meaning long-term effects are not fully established.

Key Studies & References

  1. Proton pump inhibitor therapy for peptic ulcer disease in adults

Frequently Asked Questions (FAQ)

Common questions about Omeran (FAQ)


Q: How long does it take for Omeran to start working?

Official information indicates that the drug begins to inhibit acid secretion in the stomach rapidly, often within one hour after a dose is taken. The medicine's maximum effect on reducing acid output is typically reached within two hours. While effects are sustained, official guidelines for short-term use note that it can take one to four days for some people to feel the full benefit.


Q: Is Omeran safe for people with liver problems?

Regulatory documents address the use of this medicine in patients with hepatic impairment (liver issues), noting that drug exposure in the body is increased in these cases. Official labels note that a dose reduction may be considered for certain treatment scenarios, such as the maintenance of healing of Erosive Esophagitis, due to the potential for increased exposure.


Q: Can people with kidney issues take Omeran?

According to official documentation, a general dose adjustment is not usually needed for patients with impaired renal function (kidney issues). However, rare instances of serious kidney inflammation, known as acute tubulointerstitial nephritis, have been reported in safety data.


Q: Why does the official documentation mention certain drug classes should be avoided with Omeran?

Official warnings about other medicines are based on two main effects. Firstly, Omeran can block the body's natural processes (specifically the CYP2C19 enzyme) used to break down many other drugs. Secondly, because it significantly reduces stomach acid, it also reduces the absorption of medicines that require an acidic environment to be effective.


Q: Is it normal to feel a bit nauseous when starting Omeran?

Regulatory safety profiles classify nausea/vomiting as a Common side effect. Although official documentation does not focus only on the very first few days of treatment, this classification indicates that nausea is one of the more frequently reported effects overall.


Q: Can elderly patients use Omeran?

The use of the medicine in older adults (geriatric patients) has not been limited by specific safety concerns in official studies. However, regulatory information does note that elderly patients may be more sensitive to the medicine's effects compared to younger adults.


Q: Is Omeran the same as other similar medicines?

The active ingredient in Omeran is Omeprazole, which is classified within a group of medicines known as Proton Pump Inhibitors (PPIs). Medicines in this class are considered similar because they all share the same primary mechanism of action: blocking the final step of acid production in the stomach to achieve long-term acid control.


Q: What is the difference between Omeran and a placebo in studies?

In clinical trials, Omeran is compared to a placebo (an inactive substance) to measure its specific effects. The difference is tracked by monitoring patient-reported outcomes, such as the reduction in symptom severity, or by measuring physical changes, such as the healing patterns of ulcers or the lining of the esophagus.


Q: Is Omeran available over the counter?

The availability status of the medicine varies. In some regions, the drug is available in two forms: a higher-dose, prescription-only product and a lower-dose, over-the-counter (OTC) product that is intended for the short-term treatment of frequent heartburn.


Q: Can I drink alcohol while taking Omeran?

Official drug information generally does not list a formal, direct interaction between this medicine and alcohol. It is also noted that consuming alcohol may worsen the symptoms of the underlying acid-related conditions that the medicine is intended to manage.


Q: Are there any vitamins or supplements that interact with Omeran?

Regulatory sources advise caution regarding the herbal supplement St. John's Wort, as it may potentially reduce the medicine's effectiveness. Furthermore, the long-term use of this drug is associated with an increased risk of developing a deficiency in both Vitamin B12 and magnesium.


Q: What happens if I stop taking Omeran suddenly?

Studies on patients who take the medicine for a long period show that abrupt cessation can lead to rebound acid hypersecretion. This means the stomach can temporarily produce acid at a rapid, increased rate, which may cause a sudden return or worsening of the original symptoms.


Q: What is the maximum amount of time Omeran has been studied in trials?

While typical recommended treatment periods are shorter (e.g., four to eight weeks), some official labels reference that the drug has been used continuously for more than five years in clinical settings. The documentation notes that long-term outcomes for general use are less fully established in initial controlled studies.


Q: Is Omeran a controlled substance?

The active ingredient in Omeran, Omeprazole, is classified by regulatory agencies as a Proton Pump Inhibitor. It is not listed as a controlled substance by major government drug agencies.


Q: Does Omeran affect blood pressure?

Official postmarketing safety reports have included rare observations of elevated blood pressure (hypertension) as a potential effect. Regulatory bodies collect such reports, but the exact relationship between the medicine and blood pressure changes remains uncertain and is subject to ongoing review.


Q: Can Omeran cause mood changes?

Official safety data for the medicine includes effects on the central nervous system. Uncommon effects such as insomnia and rare effects classified under psychiatric disorders, such as aggression or hallucinations, have been reported in regulatory documents.


Q: Is the onset of effect always the same for everyone taking Omeran?

Official guidelines acknowledge that individual variability is expected in response to the medicine. While the drug starts working rapidly for most people, the time to achieve full symptom relief can range from one to four days, meaning the speed of effect may differ among individuals.


Q: Are there any specific foods that must be avoided with Omeran?

Official documentation does not list any specific foods that are formally prohibited due to a dangerous drug interaction. However, regulatory instructions specify that oral forms must be taken before eating to ensure proper absorption.


Q: Do people gain weight while taking Omeran?

Regulatory safety documents have listed weight increase as a very rare side effect in postmarketing reports. The evidence suggests that weight changes may be more commonly reported with longer periods of use, although the precise mechanism for this pattern is not fully established.

How should Omeran be stored and disposed of?

How to Store and Dispose of Omeran

Official regulatory documents define specific conditions for the storage and disposal of Omeprazole (Omeran) to ensure product stability and safety.

Required Storage Conditions

Requirement Specific Mandate
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F).
Protection Protect from moisture and avoid exposure to temperatures outside the specified range.
Packaging Keep in the original, tightly closed container and out of the sight and reach of children.

Official Disposal Rules

Disposal of unused or expired Omeran must follow federal guidelines. The preferred method is utilizing a drug take-back program or authorized collection site. If these options are unavailable, the medication must be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a container, and placed in the household trash. The product is not on the list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omeran found in:

A-Z Index: